Nektar Therapeutics (NKTR US): A Good Buying Option in Immuno-Oncology Therapeutic Area

Nektar presented favorable clinical data for its lead candidate, bempeg at a global healthcare conference recently. Bempeg, a potential blockbuster drug, is expected to get approvals starting 2023.

SUMMARY

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

• Unlimited Research Summaries
• Personalised Alerts
• Custom Watchlists
• Company Analytics & News
• Events & Webinars

Trusted by:

SMARTKARMA PREVIEW PASS

Sign Up with LinkedIn

or

First NameLast nameEmail

Sign Up with EmailBy signing up, you agree to our
Terms of Use and Privacy Policy.

Trusted by:

Already have an account? Sign In Now

---